Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Sep 4;83(7):847–852. doi: 10.1054/bjoc.2000.1402

Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients withelanoma

M D Boyano 1, M D Garcia-Vázquez 1, T López-Michelena 1, J Gardeazabal 2, J Bilbao 3, M L Cañavate 1, A García De Galdeano 1, R Izu 2, L Díaz-Ramón 2, J A Raton 2, J L Díaz-Pérez 2
PMCID: PMC2374688  PMID: 10970683

Abstract

Serum soluble interleukin-2 receptor (sIL-2R), intercellular adhesion molecule-1 (sICAM-1) and interleukin-10 (IL-10) have each been reported as useful markers for melanoma progression. To evaluate the clinical relevance of these three markers, we simultaneously analysed their serum levels in patients with melanoma. A longitudinal study with a 3-year follow-up was performed and different stages of the disease were considered. Mean values of sIL-2R were significantly higher than in normal controls in all stages and correlated with the disease progression. The prognosis of patients with levels > 529 U/ml of sIL-2R was significantly poorer than in patients with sIL-2R levels < 529 U/ml. Levels of sICAM-1 were also elevated in melanoma patients, specially at the time of the metastatic disease. Serum IL-10 levels were more frequently detectable in the patients that developed metastasis during follow-up, and the prognosis of patients with detectable IL-10 levels was significantly poorer than in those patients with IL-10 undetected levels. Statistical analysis based on Logistic and Cox regression models showed that only sex, stage and sIL-2R value are factors significantly associated with metastatic progression. Moreover, high levels of sIL-2R could be a risk factor for malignant progression in melanoma. © 2000 Cancer Research Campaign

Keywords: sIL-2R, sICAM-1, IL-10, biological prognostic factors, melanoma progression

Full Text

The Full Text of this article is available as a PDF (103.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alileche A., Plaisance S., Han D. S., Rubinstein E., Mingari C., Bellomo R., Jasmin C., Azzarone B. Human melanoma cell line M14 secretes a functional interleukin 2. Oncogene. 1993 Jul;8(7):1791–1796. [PubMed] [Google Scholar]
  2. Altomonte M., Colizzi F., Esposito G., Maio M. Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. N Engl J Med. 1992 Sep 24;327(13):959–959. doi: 10.1056/NEJM199209243271314. [DOI] [PubMed] [Google Scholar]
  3. Banks R. E., Gearing A. J., Hemingway I. K., Norfolk D. R., Perren T. J., Selby P. J. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer. 1993 Jul;68(1):122–124. doi: 10.1038/bjc.1993.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Becker J. C., Dummer R., Hartmann A. A., Burg G., Schmidt R. E. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol. 1991 Dec 15;147(12):4398–4401. [PubMed] [Google Scholar]
  5. Boyano M. D., García-Vázquez M. D., Gardeazabal J., García de Galdeano A., Smith-Zubiaga I., Cañavate M. L., Raton J. A., Bilbao I., Díaz-Pérez J. L. Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma. Oncology. 1997 Sep-Oct;54(5):400–406. doi: 10.1159/000227726. [DOI] [PubMed] [Google Scholar]
  6. Burton J., Goldman C. K., Rao P., Moos M., Waldmann T. A. Association of intercellular adhesion molecule 1 with the multichain high-affinity interleukin 2 receptor. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7329–7333. doi: 10.1073/pnas.87.18.7329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen Q., Daniel V., Maher D. W., Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer. 1994 Mar 1;56(5):755–760. doi: 10.1002/ijc.2910560524. [DOI] [PubMed] [Google Scholar]
  8. Dummer W., Becker J. C., Schwaaf A., Leverkus M., Moll T., Bröcker E. B. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 1995 Feb;5(1):67–68. doi: 10.1097/00008390-199502000-00008. [DOI] [PubMed] [Google Scholar]
  9. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 1991 Aug;5(11):2567–2574. doi: 10.1096/fasebj.5.11.1868981. [DOI] [PubMed] [Google Scholar]
  10. Fierro M. T., Lisa F., Novelli M., Bertero M., Bernengo M. G. Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal study. Dermatology. 1992;184(3):182–189. doi: 10.1159/000247537. [DOI] [PubMed] [Google Scholar]
  11. Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991 Dec 1;147(11):3815–3822. [PubMed] [Google Scholar]
  12. Fiorentino D. F., Zlotnik A., Vieira P., Mosmann T. R., Howard M., Moore K. W., O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 1991 May 15;146(10):3444–3451. [PubMed] [Google Scholar]
  13. García de Galdeano A., Boyano M. D., Smith-Zubiaga I., Cañavate M. L. B16F10 murine melanoma cells express interleukin-2 and a functional interleukin-2 receptor. Tumour Biol. 1996;17(3):155–167. doi: 10.1159/000217978. [DOI] [PubMed] [Google Scholar]
  14. Giavazzi R., Chirivi R. G., Garofalo A., Rambaldi A., Hemingway I., Pigott R., Gearing A. J. Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. Cancer Res. 1992 May 1;52(9):2628–2630. [PubMed] [Google Scholar]
  15. Harning R., Mainolfi E., Bystryn J. C., Henn M., Merluzzi V. J., Rothlein R. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res. 1991 Sep 15;51(18):5003–5005. [PubMed] [Google Scholar]
  16. Howard M., O'Garra A., Ishida H., de Waal Malefyt R., de Vries J. Biological properties of interleukin 10. J Clin Immunol. 1992 Jul;12(4):239–247. doi: 10.1007/BF00918147. [DOI] [PubMed] [Google Scholar]
  17. Huang S., Xie K., Bucana C. D., Ullrich S. E., Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res. 1996 Dec;2(12):1969–1979. [PubMed] [Google Scholar]
  18. Johnson J. P., Stade B. G., Holzmann B., Schwäble W., Riethmüller G. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci U S A. 1989 Jan;86(2):641–644. doi: 10.1073/pnas.86.2.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Josimovic-Alasevic O., Herrmann T., Diamantstein T. Demonstration of two distinct forms of released low-affinity type interleukin 2 receptors. Eur J Immunol. 1988 Nov;18(11):1855–1857. doi: 10.1002/eji.1830181133. [DOI] [PubMed] [Google Scholar]
  20. Kageshita T., Yoshii A., Kimura T., Kuriya N., Ono T., Tsujisaki M., Imai K., Ferrone S. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res. 1993 Oct 15;53(20):4927–4932. [PubMed] [Google Scholar]
  21. Kerbel R. S. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol. 1992 Sep;141(3):519–524. [PMC free article] [PubMed] [Google Scholar]
  22. Ladányi A., Nagy J. O., Jeney A., Tímár J. Cytokine sensitivity of metastatic human melanoma cell lines-- simultaneous inhibition of proliferation and enhancement of gelatinase activity. Pathol Oncol Res. 1998;4(2):108–114. doi: 10.1007/BF02904703. [DOI] [PubMed] [Google Scholar]
  23. Natali P., Nicotra M. R., Cavaliere R., Bigotti A., Romano G., Temponi M., Ferrone S. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res. 1990 Feb 15;50(4):1271–1278. [PubMed] [Google Scholar]
  24. Plaisance S., Rubinstein E., Alileche A., Han D. S., Sahraoui Y., Mingari M. C., Bellomo R., Rimoldi D., Colombo M. P., Jasmin C. Human melanoma cells express a functional interleukin-2 receptor. Int J Cancer. 1993 Aug 19;55(1):164–170. doi: 10.1002/ijc.2910550129. [DOI] [PubMed] [Google Scholar]
  25. Rubin L. A., Nelson D. L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990 Oct 15;113(8):619–627. doi: 10.7326/0003-4819-113-8-619. [DOI] [PubMed] [Google Scholar]
  26. Sato T., McCue P., Masuoka K., Salwen S., Lattime E. C., Mastrangelo M. J., Berd D. Interleukin 10 production by human melanoma. Clin Cancer Res. 1996 Aug;2(8):1383–1390. [PubMed] [Google Scholar]
  27. Schadendorf D., Diehl S., Zuberbier T., Schadendorf C., Henz B. M. Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology. 1996;192(2):89–93. doi: 10.1159/000246328. [DOI] [PubMed] [Google Scholar]
  28. Staunton D. E., Dustin M. L., Erickson H. P., Springer T. A. The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell. 1990 Apr 20;61(2):243–254. doi: 10.1016/0092-8674(90)90805-o. [DOI] [PubMed] [Google Scholar]
  29. Taga K., Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol. 1992 Feb 15;148(4):1143–1148. [PubMed] [Google Scholar]
  30. Timonen T., Patarroyo M., Gahmberg C. G. CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. J Immunol. 1988 Aug 1;141(3):1041–1046. [PubMed] [Google Scholar]
  31. Tsujisaki M., Imai K., Hirata H., Hanzawa Y., Masuya J., Nakano T., Sugiyama T., Matsui M., Hinoda Y., Yachi A. Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin Exp Immunol. 1991 Jul;85(1):3–8. doi: 10.1111/j.1365-2249.1991.tb05673.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vánky F., Wang P., Patarroyo M., Klein E. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother. 1990;31(1):19–27. doi: 10.1007/BF01742491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Yue F. Y., Dummer R., Geertsen R., Hofbauer G., Laine E., Manolio S., Burg G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer. 1997 May 16;71(4):630–637. doi: 10.1002/(sici)1097-0215(19970516)71:4<630::aid-ijc20>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES